0IV3.L

Geron Corporation [0IV3.L] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

0IV3.L Stock Summary

Top 10 Correlated ETFs

0IV3.L

Top 10 Correlated Stocks

0IV3.L

In the News

0IV3.L Financial details

Company Rating
-
Market Cap
2.16B
Income
-184.13M
Revenue
237K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
141
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-7.06
Quick Ratio
3.51
Current Ratio
3.75
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.32
EPS next Y
-
EPS next Q
-
EPS this Y
-13.51%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-2.33%
Revenue last 5Y
-12.42%
Revenue Q/Q
-85.98%
EPS Q/Q
13.07%
-
-
-
-
SMA20
-19.16%
SMA50
-51.96%
SMA100
-66.58%
Inst Own
-
Inst Trans
-
ROA
-
ROE
-
ROC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.731-4.005
52W High
-65.75%
52W Low
+37%
RSI
42.7
Rel Volume
0.22
Avg Volume
12.48K
Volume
2.72K
Perf Week
10.48%
Perf Month
-19.41%
Perf Quarter
-66.83%
Perf Half Y
-67.22%
-
-
-
-
Beta
0.608
-
-
Volatility
0.03%, 0.19%
Prev Close
0%
Price
1.37
Change
-1.44%

Something similar

Top by Market Cap
META
FB2A.DE
3V64.DE
AAPL
CMC.DE
Top Correlated ETFs
2B70.DE
IEVD.DE
PRAC.L
DRDR.L
PRFD.L
Top Correlated Stocks
KER.PA
TUB.BR
PPX.DE
WAF.DE
0I14.L
Similar Market Cap
AMPH
RAJSREESUG.NS
FELIX
LDAG.L
RAJMET.NS

Company Profile

Healthcare Medical - Pharmaceuticals
  • Volume Average 12.48K
  • Market Capitalization 2.16B
  • Employee 141
  • CEO Dr. John A. Scarlett M.D.
  • Headquarters Foster City,CA,US
  • IPO Date 2018-01-29
  • Website https://www.geron.com

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.